innovation outpost

Photos: Houston hospital opens tech hub in the Ion

Houston Methodist opened a new tech hub in the Ion this week. Photo by Shannon O’Hara/Ion

A Houston hospital has opened an innovation outpost in the Ion this week in order to showcase health tech innovation and connect with Houston innovators.

The Houston Methodist Tech Hub at Ion hub has officially opened. The 1,200-square-foot space was created in addition to the Center for Innovation Technology Hub that's in Houston Methodist’s flagship location in the Texas Medical Center, which opened in February 2020.

The new space, located on the lower level of the Ion, exists to serve as a common ground for innovators across industries to promote collisions and innovation, as well as interaction with Houston Methodist team members

“Our new Tech Hub at Ion supports not only our commitment to the Houston innovation community but also to the rapidly shifting healthcare industry,” Michelle Stansbury, vice president of innovation and IT applications at Houston Methodist, says in a statement. “We know we can’t solve the healthcare challenges of the future if we confine ourselves within our hospital walls or even within our own industry.

"We look forward to the collaborative space our new Tech Hub will provide and the future programming opportunities we can create together to inspire, challenge, and foster a spirit of innovation in our city.”

The new hub, according to the news release, also will host educational events, reverse pitch sessions, and more. Visitors can schedule a time to view the space or connect with the Houston Methodist innovation team by filling out a form online.

The hub, which was originally announced last year, is the latest partner to open within the Ion's space. Earlier this year, the organization announced other new tenants.

“Houston Methodist’s space at the Ion opens up even more opportunities for our start-up and entrepreneur community to embed and gain exposure to the latest innovations in health care, health technology, and digital health,” Jan E. Odegard, executive director of Ion, says. “This partnership and opportunity provided by Houston Methodist, a leading healthcare organization in the country, is a testament to the ecosystem we’re building and the talent within our building. Furthermore, Houston Methodist’s approach and appetite for cross-industry innovation and collaboration meshes seamlessly with the Ion’s ongoing plans to support Houston’s growing innovation community in industries and fields that will change the world.”

Both of Houston Methodist's tech hubs will showcase its latest technologies its implementing in its hospital system, including the "hospital of the future" it's building out in Cypress.

Collaborative effort

Photo by Shannon O’Hara/Ion

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted